An update on adjuvant systemic therapies in melanoma.

Melanoma Manag 2019 Nov 13;6(3):MMT28. Epub 2019 Nov 13.

Department of Medical Oncology, The Alfred Hospital, Melbourne 3004, Australia.

There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize treatment strategies in all stages of the disease to provide better patient outcomes. The role of adjuvant therapy in patients with resected stage 3 melanoma is a rapidly evolving field. Interferon was the first agent shown to have any utility in this space, however, recent advances in both targeted therapies and immunotherapies have led to a number of practice changing adjuvant trials in resected stage 3 disease.

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2019-0009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891936PMC
November 2019

Publication Analysis

Top Keywords

resected stage
8
patients resected
4
adjuvant therapy
4
therapy patients
4
stage melanoma
4
rapidly evolving
4
melanoma rapidly
4
role adjuvant
4
outcomes the role
4
strategies stages
4
treatment strategies
4
optimize treatment
4
stages disease
4
disease provide
4
patient outcomes the
4
provide better
4
evolving field
4
field interferon
4
practice changing
4
number practice
4

References

(Supplied by CrossRef)

McMasters KM et al.
Ann. Surg. 2010

Mocellin S et al.
Cochrane Database Syst. Rev. 2013

Similar Publications